selected publications
-
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 20 -
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Cancer.
2019
Academic Article
GET IT
Times cited: 30 -
Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Current treatment options in oncology.
2018
Review
GET IT
Times cited: 13 -
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2018
Academic Article
GET IT
Times cited: 5 -
BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary.
Histopathology.
2018
Academic Article
GET IT
Times cited: 19 -
CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.
AJR. American journal of roentgenology.
2018
Academic Article
GET IT
Times cited: 23 -
Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.
Gynecologic oncology research and practice.
2018
Review
GET IT
Times cited: 36 -
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Academic Article
GET IT
Times cited: 49 -
The roles of pathology in targeted therapy of women with gynecologic cancers.
Gynecologic oncology.
2017
Review
GET IT
Times cited: 22 - Corrigendum to "Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation" [Gynecol. Oncol. Rep. 22 (2017) 9-12]. Gynecologic oncology reports. 2017 Academic Article GET IT
-
Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation.
2017
GET IT
Times cited: 2 -
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
Ophthalmology.
2017
Academic Article
GET IT
Times cited: 80 -
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.
Cancer investigation.
2016
Academic Article
GET IT
Times cited: 10 - Low-Grade Serous Carcinoma of the Ovary. Oncology (Williston Park, N.Y.). 2016 Academic Article GET IT
-
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
2015
GET IT
Times cited: 76 -
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2014
Academic Article
GET IT
Times cited: 33 -
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2014
Academic Article
GET IT
Times cited: 66 -
Management of advanced uterine leiomyosarcoma.
Current opinion in oncology.
2014
Review
GET IT
Times cited: 15 -
Targeted therapies for treatment of recurrent ovarian cancer.
Clinical advances in hematology & oncology : H&O.
2014
Review
GET IT
Times cited: 12 -
Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome.
Gynecologic oncology.
2012
Academic Article
GET IT
Times cited: 55 -
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Cancer.
2012
Academic Article
GET IT
Times cited: 147 -
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
2012
Academic Article
GET IT
Times cited: 10 -
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
Gynecologic oncology.
2012
Academic Article
GET IT
Times cited: 26 -
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Cancer.
2011
Academic Article
GET IT
Times cited: 71 -
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Investigational new drugs.
2011
Academic Article
GET IT
Times cited: 8 -
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
Gynecologic oncology.
2011
Academic Article
GET IT
Times cited: 10 -
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
Immunotherapy.
2011
Review
GET IT
Times cited: 20